Page last updated: 2024-12-05

gallamine triethiodide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Gallamine triethiodide is a neuromuscular blocking agent that acts by competitively inhibiting acetylcholine at the nicotinic receptors of the neuromuscular junction. It is used as a muscle relaxant in anesthesia, particularly for intubation and surgery. The synthesis involves the quaternization of the tertiary amine groups of gallamine with ethyl iodide. The effects of gallamine triethiodide are primarily related to its ability to paralyze skeletal muscles. It is also known to have some anticholinergic effects, such as dry mouth and blurred vision. The importance of this compound lies in its ability to provide muscle relaxation, which is crucial for a wide range of medical procedures. However, its use is limited by its long duration of action and the potential for adverse effects, including cardiovascular instability. Studies on gallamine triethiodide focus on its pharmacological properties, therapeutic applications, and potential side effects. The compound remains a valuable tool in anesthesia, but its use is declining due to the availability of newer and safer muscle relaxants.'

Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6172
CHEMBL ID1200993
MeSH IDM0008954
PubMed CID3450
CHEMBL ID360055
CHEBI ID94609
SCHEMBL ID12638600
MeSH IDM0008954

Synonyms (223)

Synonym
relaxan
pyrolaxon
3697 r.p.
gallamone triethiodide
nsc-102690
gallamin triethiodide
sincurarine
gallamine-3eti
f 2559
miowas g
gallaflex
retensin
hl 8583
remyolan
pirolakson
gallamin
benzkurin
rp 3697
flacedil
parexyl
fourneau 2559
benzcurine iodide
tricuran
syncurarine
gallaminum triaethoiodatum
pyrogallol 1,2,3-(diethylaminoethyl ether) trisethyl iodide
ammonium, (v-phenenyltris(oxyethylene)tris(triethyl-, triiodide
gallamine triethiodide [inn]
1,2,3-tris(2-triethylammonium ethoxy)benzene triiodide
hsdb 3229
tri(beta-diethylaminoethoxy)-1,2,3-benzene tri-iodoethylate
nsc 102690
ethanaminium, 2,2',2'-(1,2,3-benzenetriyltris(oxy))tris(n,n,n-triethyl)-, triiodide
triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene [french]
einecs 200-605-1
(v-phenenyltris(oxyethylene))tris(triethylammonium) triiodide
triethiodure de gallamine [inn-french]
gallamonium iodide
1,2,3-tris(2-diethylaminoethoxy)benzene triethiodide
1,2,3-tri(beta-diethylaminoethoxy)benzene triethiodide
triiodoethylate de gallamine [french]
gallamine triethyl iodide
gallamoni jodidum
(v-phenenyltris(oxyethylene))tris(triethylammonium iodide)
gallaminum triaethjodidum
gallaminii iodidum
pyrogallol 1,2,3-(diethylaminoethyl ether) tris(ethyliodide)
2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(n,n,n-triethylethanaminium) triiodide
triethioduro de galamina [inn-spanish]
triiodoethylate of tri(diethylaminoethyloxy)-1,2,3-benzene
ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(n,n,n-triethyl-, triiodide
1,2,3-tris(diethylaminoethoxy)benzene triethiodide
gallamini triethiodidum [inn-latin]
ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(n,n,n-triethyl)-, triiodide
(v-phenenyltris(oxyethylene))tris(triethylammoniumiodide)
1,2,3-tris(2-diethylaminoethoxy)benzene tris(ethyliodide)
gallamina triodoetilato [dcit]
tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene [french]
ammonium, (v-phenenyltris(oxyethylene))tris(triethyl-, triiodide
gallamine triethiodide
2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(n,n,n-triethylethanaminium) triiodide
EU-0100550
gallamine triethiodide, >=98% (tlc), powder, muscarinic receptor antagonist
65-29-2
PRESTWICK_237
triethyl iodide, gallamine
triethiodide, gallamine
iodide, gallamine triethyl
iodide, gallamonium
DB00483
gallamine triethiodide (usp)
flaxedil (tn)
D02292
NCGC00093937-01
G 8134 ,
HMS2091H09
gallamini triethiodidum
CHEMBL1200993
HMS502A12
HMS1568O16
HMS3261N21
HMS2095O16
unii-q3254x40x2
gallamina triodoetilato
triethioduro de galamina
triethiodure de gallamine
gallamine triethiodide [usp:inn]
q3254x40x2 ,
tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene
3.697 r.p.
triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene
tox21_112040
dtxcid303089
dtxsid5023089 ,
CCG-40105
LP00550
gallamine triethiodide [orange book]
gallamine triethiodide [who-dd]
gallamini triethiodidum [who-ip latin]
gallamine triethiodide [hsdb]
gallamine triethiodide [vandf]
gallamine triethiodide [usp impurity]
gallamine triethiodide [mart.]
gallamine triethiodide [who-ip]
gallamine triethiodide [mi]
ethanaminium, 2,2',2''-(benzene-1,2,3-triyltris(oxy))tris(n,n,n-triethyl-, triiodide
[v-phenenyltris(oxyethylene)]tris[triethylammonium] triiodide
S2471
HY-B0416
tox21_112040_1
NCGC00015482-07
tox21_500550
NCGC00261235-01
W-104798
2,2',2''-(benzene-1,2,3-triyltris(oxy))tris(n,n,n-triethylethan-1-aminium) iodide
AKOS026749935
SR-01000075317-1
sr-01000075317
gallamine triethiodide, united states pharmacopeia (usp) reference standard
gallamine triethiodide, european pharmacopoeia (ep) reference standard
HMS3656G04
(2-{2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy}ethyl)triethylazanium triiodide
AS-57694
SR-01000075317-6
SR-01000075317-3
HMS3712O16
SW196544-3
2,2',2''-(benzene-1,2,3-triyltris(oxy))tris(n,n,n-triethylethanaminium) iodide
FT-0703297
Q3094785
gallamine triethiodide (flaxedil)
6b,7a-dihydro-7h-cycloprop[a]acenaphthylene-7-carboxylicacidethylester
HMS3884B21
C76041
2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;triiodide
m03ac02
gallaminum triethoidatum
(v-phenenyltris(oxyethylene))tris(triethylammonium triiodide)
triethiodure de gallamine (inn-french)
gallamini triethiodidum (inn-latin)
gallamine triethiodide (usp:inn)
gallamine triethiodide (usp impurity)
triiodoathylate de gallamine
trietioduro de galamina
gallamine (base)
(v-phenenyltris(oxyethylene))tris(triethylammonium)iodide
gallamin triethiodid
triethioduro de galamina (inn-spanish)
gallamine triethiodide (mart.)
G0554
Z1546616201
triiodoethylate de gallamine
flaxedil
gallamine iodide
gallamine triiodoethylate
bdbm50149891
2,2'',2''''-[1,2,3-benzene-triyltris(oxy)]tris[n,n,n-triethylethanaminium]
AB00053799-08
2-[2,6-bis(2-triethylazaniumylethoxy)phenoxy]ethyl-triethylazanium
gtpl356
KBIO1_000650
DIVK1C_000650
SPECTRUM_000823
BPBIO1_000324
PRESTWICK2_000157
BSPBIO_000294
cas-65-29-2
NCGC00015482-02
lopac-g-8134
NCGC00015482-01
IDI1_000650
BSPBIO_002058
LOPAC0_000550
PRESTWICK3_000157
SPECTRUM5_000748
AB00053799
NCGC00163245-01
KBIO2_003871
KBIO3_001278
KBIO2_001303
KBIO2_006439
KBIOGR_000962
KBIOSS_001303
SPBIO_001096
PRESTWICK0_000157
SPECTRUM4_000561
SPECTRUM2_001078
PRESTWICK1_000157
NINDS_000650
SPBIO_002233
SPECTRUM3_000439
NCGC00162183-01
HMS2089F21
NCGC00015482-04
L001056
CHEMBL360055 ,
2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium
gallamine triethiiodide
CCG-204640
NCGC00015482-03
NCGC00015482-05
lopac g-8134
7006-17-9
vyj027lz05 ,
unii-vyj027lz05
triethylgallamine
ethanaminium, 2,2',2''-(benzene-1,2,3-triyltris(oxy))tris(n,n,n-triethyl-
AB00053799-09
lopac g 8134
DTXSID5048392
SCHEMBL12638600
2,2',2''-(1,2,3-benzenetriyltrisoxy)tris(n,n,n-triethylethanaminium)
AB00053799_11
AB00053799_10
2-[2,3-bis[2-(triethylammonio)ethoxy]phenoxy]ethyl-triethylammonium
CHEBI:94609
SBI-0050533.P004
2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(n,n,n-triethylethanaminium)
2,2',2''-(benzene-1,2,3-triyltris(oxy))tris(n,n,n-triethylethan-1-aminium)
Q27077765
NCGC00015482-16
gallamine-triethiodide
2-[2,6-bis(2-triethylammonioethoxy)phenoxy]ethyl-triethyl-azanium

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
"Data about plasma concentration, renal and biliary elimination of tubocurarine, gallamine, alcuronium and pancuronium are taken from the literature for synoptical pharmacokinetic analysis."( Comparative clinical pharmacokinetics of tubocurarine, gallamine, alcuronium and pancuronium.
Agoston, S; Buzello, W, 1978
)
0.26
" With the use of sophisticated pharmacokinetic and pharmacodynamic models good relationships have been demonstrated between plasma concentrations of the relaxants throughout the entire range of relaxant response."( Clinical pharmacokinetics of the non-depolarising muscle relaxants.
Ramzan, MI; Shanks, CA; Somogyi, AA; Triggs, EJ; Walker, JS,
)
0.13
" A significant increase in the steady-state volume of distribution of gallamine was noted in patients with biliary obstruction as compared to the group without obstruction, but no significant differences between the groups were apparent for the biologic half-life and total clearance of the drug."( Pharmacokinetics and pharmacodynamics of gallamine triethiodide in patients with total biliary obstruction.
Ramzan, IM; Shanks, CA; Triggs, EJ, 1981
)
0.26
" No significant differences were noted when the model-independent pharmacokinetic parameters between the two groups of patients were compared with the exception of the distribution phase half-life (t1/2 alpha) (6."( Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses.
Ramzan, MI; Shanks, CA; Triggs, EJ, 1980
)
0.26
" No significant differences in the various pharmacokinetic parameters were noted."( Pharmacokinetic studies in man with gallamine triethiodide. II. Single 4 and 6 mg/kg i.v. doses.
Ramzan, MI; Shanks, CA; Triggs, EJ, 1980
)
0.26

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"This experiment was carried out upon the male-adulte-AF SPF-Wister Rat, anesthetized by the use of pentobarbital-Na at the only dosage of 40 mg/kg/IP and put under artificial ventilation."( [Variations in the activity of various curarizing substances as a function of the time of administration].
Agopian, B; Bouyard, P; Bruguerolle, B; Jadot, G; Mesdjian, E; Valli, M, 1975
)
0.25
"Intravenous dose-response relationships were used to correlate neuromuscular paralysis with effects on autonomic mechanisms in anaesthetized cats."( Effects on non-depolarizing neuromuscular blocking agents on peripheral autonomic mechanisms in cats.
Chapple, DJ; Hughes, R, 1976
)
0.26
" Recordings from CI-744 dosed seals displayed a well-demarcated developmental sequence of VER's, contrary to VER's recorded in flaxedilized seals."( Visual evoked response (VER) changes during maturation in the Weddell seal.
Gruenau, SP; Shurley, JT, 1976
)
0.26
" Gallamine caused parallel rightward shifts of the dose-response curves to the agonists, with no depression of the maximal response."( The inhibitory effect of gallamine on muscarinic receptors.
Clark, AL; Mitchelson, F, 1976
)
0.26
" There were no fasciculations with this dosage and conditions for endotracheal intubation were excellent."( Inhibition of suxamethonium relaxation by tubocurarine and gallamine pretreatment during induction of anaesthesia in man.
Pauca, AL; Reynolds, RC; Strobel, GE, 1975
)
0.25
" All these compounds led to abnormalities of the cervical vertebrae; at higher dosage interference with normal morphogenesis involved the whole vertebral column."( Cholinomimetic teratogens: studies with chicken embryos.
Landauer, W, 1975
)
0.25
" A programmed level of muscle paralysis is therefore possible for use in physiological and pharmacological experiments, and in clinical practice where precise control of the degree of paralysis together with minimal dosage is advantageous."( Computer controlled muscle relaxation: a comparison of four muscle relaxants in the sheep.
Brown, WA; Cass, NM; Coles, JR; Lampard, DG, 1976
)
0.26
" Dose-response lines in response to the two agonists, expressed as percent maximal contraction, did not differ among the groups."( Muscarinic-receptor functioning in tracheas from normal and ovalbumin-sensitive guinea pigs.
Biggs, DF; Yang, ZJ, 1991
)
0.28
" The dose-response values obtained were fitted to a regression embedded in a split plot factorial experimental design such as both to control and to measure effects of variation among preparations, order of administration, time, and level of block."( Interaction among agents that block end-plate depolarization competitively.
Waud, BE; Waud, DR, 1985
)
0.27
" In the presence of both antagonists, a supraadditive shift in the carbamylcholine dose-response curve was demonstrated for the two responses, a result suggestive of an allosteric mode of interaction between gallamine and NMS binding sites."( Mixed competitive and allosteric antagonism by gallamine of muscarinic receptor-mediated second messenger responses in N1E-115 neuroblastoma cells.
el-Fakahany, EE; Lee, NH, 1989
)
0.28
"The dose-response curve for the muscarine-induced depolarisation of the rat isolated superior cervical ganglion, studied over the concentration range of 3 nM-1 mM, was biphasic."( Biphasic dose-response curve to muscarine on the rat superior cervical ganglion.
Gilbert, MJ; Newberry, NR, 1989
)
0.28
" Dose-response curves to carbachol, muscarine and oxotremorine were shifted to the right by gallamine and pirenzepine in a parallel manner with no change in maximal response ostensibly indicating simple competitive inhibition."( Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea.
Boselli, C; Kenakin, T, 1989
)
0.28
" Gallamine caused parallel shifts to the right in the dose-response curves for inhibition of adenylate cyclase activity by the highly efficacious muscarinic agonist oxotremorine-M and the partial agonist Bm 5 [N-methyl-N-(1-methyl-4-pyrrolidino)-2-butynyl acetamide]."( Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium.
Ehlert, FJ, 1988
)
0.27
" In contrast, a combination of methoctramine with gallamine produced a less than additive shift of the dose-response curve for carbachol, confirming that gallamine acts as an allosteric antagonist at cardiac muscarinic receptors."( Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine.
Angeli, P; Lambrecht, G; Melchiorre, C; Mutschler, E; Picchio, MT; Wess, J, 1987
)
0.27
" No evidence supporting the concept that dosage should be related to patient's weight was found."( Reduction of post-suxamethonium pain by pretreatment with four non-depolarizing agents.
Bennetts, FE; Khalil, KI, 1981
)
0.26
" For each drug at each temperature, a dose-response curve for twitch depression was constructed."( Pancuronium, unlike other nondepolarizing relaxants, retains potency at hypothermia.
Bartkowski, RR; Horrow, JC, 1983
)
0.27
"Cumulative dose-response curves were constructed for pancuronium, metocurine, d-tubocurarine and gallamine in 56 children anaesthetized with thiopentone, N2O/O2 and narcotic."( The dose response effect of long-acting nondepolarizing neuromuscular blocking agents in children.
Ali, HH; Goudsouzian, NG; Liu, LM; Martyn, JJ, 1984
)
0.27
" To explain sigmoidal dose-response curves, a two-site model is already sufficient."( Interaction of cholinergic ligands with the purified acetylcholine receptor protein. I. Equilibrium binding studies.
Maelicke, A; Prinz, H, 1983
)
0.27
" Dosage regimens have been designed using knowledge of the disposition kinetics of the relaxants to provide for continuous adequate relaxation during prolonged surgical procedures."( Clinical pharmacokinetics of the non-depolarising muscle relaxants.
Ramzan, MI; Shanks, CA; Somogyi, AA; Triggs, EJ; Walker, JS,
)
0.13
"Cumulative dose-response curves were constructed in man for tubocurarine, pancuronium, gallamine and alcuronium from data obtained during barbiturate-narcotic-nitrous oxide anaesthesia."( Dose-response curves for four neuromuscular blockers using continuous i.v. infusion.
Ramzan, MI; Shanks, CA; Triggs, EJ; Walker, JS, 1981
)
0.26
" 6 At this low dosage the rate of recovery from paralysis in renal failure patients, though similar to that noted normally, appeared to be somewhat slower in some patients."( Gallamine disposition in surgical patients with chronic renal failure.
Ramzan, MI; Shanks, CA; Triggs, EJ, 1981
)
0.26
" The dosage pattern consisted of a loading phase before any IEMG depression was detected, an onset phase during which a moderate amount of drug was required to achieve increasing paralysis, and a maintenance phase during which a substantially constant and relatively low infusion rate was required."( Dosage patterns of non-depolarizing neuromuscular blockers in the sheep.
Brown, WA; Cass, N; Lampard, DG; Ng, KC, 1980
)
0.26
"The ability to reliably and precisely control heart rate was superior with TAP compared with intermittent bolus dosing with gallamine."( Transesophageal atrial pacing (TAP) for sinus bradycardia during coronary artery bypass grafting: comparison of TAP to intermittent bolus gallamine.
Shields, JA; Tomichek, RC; Zimmerman, RE, 1995
)
0.29
" We and others have previously shown that substitution of phenylalanine for tyrosine at position 198 of the alpha subunit (alpha Y198F) leads to a rightward shift in the dose-response curve for acetylcholine-elicited currents."( Selective enhancement of the interaction of curare with the nicotinic acetylcholine receptor.
Aylwin, ML; Filatov, GN; White, MM, 1993
)
0.29
" Dose-response curves were constructed using the putatively selective antagonists pirenzepine (M1), gallamine (M2) and 4-DAMP (M3: 4-diphenyl-acetoxy-N-methylpiperidine) and compared with the non-selective blocker, atropine."( Functional characterization of peripheral muscarinic subtypes in anesthetized cats.
Koss, MC, 1997
)
0.3
" Muscarine shifted the GABA dose-response curve to the left, with the GABA EC50 decreased from 45 +/- 2 to 13 +/- 2 microM."( Enhancement of GABA-activated current by muscarine in rat dorsal root ganglion neurons.
Hu, HZ; Li, ZW; Shao, M, 1999
)
0.3
" Drug combinations containing equipotent concentrations of two agents were tested and dose-response curves were determined."( Isobolographic analysis of non-depolarising muscle relaxant interactions at their receptor site.
Dipp, NC; Fokt, RM; Kindler, CH; Paul, M; Yost, CS, 2002
)
0.31
" Gallamine at 10(-5)M concentration failed to displace the dose-response curve for carbachol-induced accumulation of inositol triphosphate (IP3)."( Methoctramine and gallamine inhibit PI hydrolysis in guinea-pig gallbladder.
Cabadak, H; Kan, B, 2005
)
0.33
" Dose-response curves of acetylcholine effect on heart rate were constructed with data from isolated heart experiments in the presence of CChP or normal blood donor (NBD) sera."( Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease.
Campos DE Carvalho, AC; Chaves, EA; Costa, PC; Gimenez, LE; Hernandez, CC; Kurtenbach, E; Masuda, MO; Nascimento, JH, 2008
)
0.35
" Gallamine caused parallel rightward shifts of the dose-response curves to the agonists, with no depression of the maximal response."( The inhibitory effect of gallamine on muscarinic receptors.
Clark, AL; Mitchelson, F, 1976
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency0.00280.707912.432431.6228AID1708
GLI family zinc finger 3Homo sapiens (human)Potency18.83360.000714.592883.7951AID1259369
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency11.21850.001022.650876.6163AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency15.08900.000214.376460.0339AID720691
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.33220.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.35480.035520.977089.1251AID504332
M-phase phosphoprotein 8Homo sapiens (human)Potency79.43280.177824.735279.4328AID488949
thioredoxin reductaseRattus norvegicus (Norway rat)Potency7.31780.100020.879379.4328AID488773; AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency10.00000.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency14.12540.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
hypothetical protein, conservedTrypanosoma bruceiPotency19.01150.223911.245135.4813AID624147
regulator of G-protein signaling 4Homo sapiens (human)Potency26.67950.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency1.06911.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency13.85520.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency37.68580.006026.168889.1251AID488953
M-phase phosphoprotein 8Homo sapiens (human)Potency13.37140.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency10.50060.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency21.45090.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.03380.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)1.38760.00001.23267.7930AID1482269; AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki1.63140.00000.690210.0000AID1482282; AID1482283; AID625152
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)3,150.00000.00000.94539.9400AID303069
AcetylcholinesteraseTetronarce californica (Pacific electric ray)Ki15.00000.00000.76714.3000AID404434
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki8.51140.00000.59729.1201AID714454
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)2,110.00000.00000.933210.0000AID303071
AcetylcholinesteraseHomo sapiens (human)Ki37.00000.00001.27869.7300AID407780
Acetylcholinesterase Bos taurus (cattle)IC50 (µMol)8,760.00000.00000.61068.7000AID404439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Sus scrofa (pig)EC50 (µMol)0.13090.01351.86256.3096AID303074
Muscarinic acetylcholine receptor M1Homo sapiens (human)EC50 (µMol)171.89000.00161.304310.0000AID714456
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesterase Bos taurus (cattle)
protein bindingAcetylcholinesterase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesterase Bos taurus (cattle)
side of membraneAcetylcholinesterase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (115)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1482282Displacement of [3H]UNSW-MK259 from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1482269Displacement of [3H]NMS from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1482283Displacement of [3H]UR-AP060 from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cell homogenate after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID714457Noncompetitive binding affinity at EGFP-fused human M1 receptor N-terminal truncated at 17 residues expressed in HEK293 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
AID404434Inhibition of Torpedo californica AChE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID303070Inhibition of Torpedo californica Acetylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID303071Inhibition of human Acetylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID714455Displacement of [3H]NMS from EGFP-fused human M1 receptor N-terminal truncated at 17 residues expressed in HEK293 cells assessed as reduction of [3H]NMS dissociation rate after 22 hrs by liquid scintillation counting relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
AID241212Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Defining determinant molecular properties for the blockade of the apamin-sensitive SKCa channel in guinea-pig hepatocytes: the influence of polarizability and molecular geometry.
AID714454Competitive inhibition of EGFP-fused human M1 receptor N-terminal truncated at 17 residues expressed in HEK293 cells after 4 hrs by FRET assay in presence of para-LRB-AC422012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
AID303073Selectivity for human butyrylcholinesterase over human butyrylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID303074Inhibition of [3H]NMS dissociation from porcine muscarinic M2 receptor2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID404439Inhibition of bovine AChE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID303072Inhibition of human butyrylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID407780Inhibition of human AChE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID714456Displacement of [3H]NMS from EGFP-fused human M1 receptor N-terminal truncated at 17 residues expressed in HEK293 cells assessed as reduction of [3H]NMS dissociation rate after 22 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
AID303069Inhibition of Electrophorus electricus Acetylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID724745Allosteric modulation of rat muscarinic M1 receptor expressed in CHO cells using [3HNMS] at 1 mM by dissociation kinetic studies2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1995Molecular pharmacology, Aug, Volume: 48, Issue:2
Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))2003Molecular pharmacology, Jul, Volume: 64, Issue:1
Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1976British journal of pharmacology, Nov, Volume: 58, Issue:3
The inhibitory effect of gallamine on muscarinic receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1345364Rat M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,337)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901063 (79.51)18.7374
1990's157 (11.74)18.2507
2000's71 (5.31)29.6817
2010's38 (2.84)24.3611
2020's8 (0.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.45 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index84.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials34 (2.36%)5.53%
Trials0 (0.00%)5.53%
Reviews37 (2.57%)6.00%
Reviews0 (0.00%)6.00%
Case Studies28 (1.94%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,343 (93.13%)84.16%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]